Crossmark

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Crossref DOI link: https://doi.org/10.1136/bmjgast-2021-000853

Published Online: 2022-02-14

Published Print: 2022-02

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Louis, Edouard

Paridaens, Kristine

Al Awadhi, Sameer

Begun, Jakob

Cheon, Jae Hee

Dignass, Axel U

Magro, Fernando

Márquez, Juan Ricardo

Moschen, Alexander R

Narula, Neeraj

Rydzewska, Grazyna

Freddi, Matthew J https://orcid.org/0000-0001-8219-1135
Travis, Simon PL
Funding

Funding for this research was provided by:

Ferring Pharmaceuticals
License Information

License valid from 2022-02-13